IDYA
IDEAYA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$32.36
+3.29%Year over year
Reported trailing growth
- Revenue
- -83.0%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +141.9%
- EBITDA
- +1.2%
- EPS
- -3.4%
Three-year CAGR
- Revenue
- +62.5%
- EBITDA
- +42.8%
- EBIT
- +51.3%
- Net income
- +58.6%
- EPS
- +61.9%
- Free cash flow
- +70.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026